Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 255

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial

Open access
Wang, Angela Yee-Moon, Fang, Fang, Chan, John, Wen, Yue-Yi, Qing, Shang, Chan, Iris Hiu-Shuen, Lo, Gladys, Lai, Kar-Neng, Lo, Wai-Kei, Lam, Christopher Wai-Kei, Yu, Cheuk-Man · 2014 · Journal of the American Society of Nephrology

Abstract

Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitamin D on patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebo-controlled trial to determine whether oral activated vitamin D reduces left ventricular (LV) mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) or matching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], -2.59 [-6.13 to 0.32] g/m(2) with paricalcitol versus -4.85 [-9.89 to 1.10] g/m(2) with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolic mitral annular velocities, and ratio of early mitral inflow velocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P<0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 μg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2013010103

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Cited by

See all 255

Metadata

Authors
Wang, A. Y.-M., Fang, F., Chan, J., Wen, Y.-Y., Qing, S., Chan, I. H.-S., Lo, G., Lai, K.-N., Lo, W.-K., Lam, C. W.-K., & Yu, C.-M.
Venue
Journal of the American Society of Nephrology
Published
2014-01
Volume
25
Issue
1
Pages
175-186
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2151974901
Cited by
255
References
46
FWCI
12.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial. https://app.cochat.ai/papers/10.1681/asn.2013010103
The paper
Wang, A. Y.-M., Fang, F., Chan, J., Wen, Y.-Y., Qing, S., Chan, I. H.-S., Lo, G., Lai, K.-N., Lo, W.-K., Lam, C. W.-K., & Yu, C.-M. (2014). Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2013010103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.